Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 21, 2005; 11(43): 6792-6799
Published online Nov 21, 2005. doi: 10.3748/wjg.v11.i43.6792
Published online Nov 21, 2005. doi: 10.3748/wjg.v11.i43.6792
Table 1 Patients’ clinical characteristics
| Age (yr) | 63 ± 8 | (48 - 74) |
| Sex ratio, M/F | 30/13 | |
| Etiology of cirrhosis, HBV/HCV/unknown | 5/32/6 | |
| Previous history of overt hepatic encephalopathy, | ||
| None/Chronic | Apr-39 | |
| Child-Pugh score | 8.0 ± 2.2 | (5 -13) |
| Laboratory examinations | ||
| Platelet (104µL) | 7.5 ± 5.1 | (8 - 31.4) |
| Albumin (g/dL) | 2.9 ± 0.5 | (1.9 - 3.9) |
| Total bilirubin (mg/dL) | 2.0 ± 2.3 | (0.5 - 13.8) |
| Cholinesterase (∆pH) | 0.36 ± 0.19 | (0.11 - 0.97) |
| Plasma ammonia (µmol/L) | 38 ± 23 | (4 - 104) |
| Prothrombin time (%) | 69.1 ± 12.8 | (31.3 - 93.5) |
| BCAA to tyrosine ratio | 3.3 ± 1.3 | (1.32 - 6.95) |
| Neuropsychological test | ||
| Trail making test (s) | 54 ± 26 | (28 - 160) |
| Digit symbol test (gross point) | 35 ± 10 | (12 - 54) |
Table 2 Clinical characteristics of BCAA and placebo groups
| BCAA group | Placebo group | |||
| Age (yr) | 64 ± 9 | (50 - 72) | 65 ± 8 | (51 - 74) |
| Sex ratio, M/F | 10/6 | 9/4 | ||
| Etiology of cirrhosis, HBV/HCV/unknown | 1/11/4 | 0/12/1 | ||
| Previous history of overt hepatic encephalopathy, None/Chronic | 14/2 | 12/1 | ||
| Child-Pugh score | 8.1 ± 2.5 | (5 - 13) | 7.8 ± 2 | (5 - 11) |
| Laboratory examinations | ||||
| Platelet (104µL) | 8.3 ± 6.8 | (3.4 - 31.4) | 7.6 ± 3.1 | (2.8 – 12.3) |
| Albumin (g/dL) | 2.8 ± 0.5 | (2.1 - 3.9) | 2.9 ± 0.4 | (2.4 - 3.9) |
| Total bilirubin (mg/dL) | 2.2 ± 3.2 | (0.8 - 13.8) | 1.9 ± 1.8 | (0.5 – 6.9) |
| Cholinesterase (∆pH) | 0.32 ± 0.16 | (0.12 - 0.64) | 0.38 ± 0.12 | (0.17 - 0.55) |
| Plasma ammonia (µmol/L) | 35 ± 20 | (9 - 79) | 34 ± 18 | (7 - 74) |
| Prothrombin time (%) | 68.9 ± 14.4 | (31.3 - 93.5) | 71.1 ± 13.4 | (51.8 – 89.2) |
| BCAA to tyrosine ratio | 3.7 ± 1.2 | (2.3 - 7) | 3 ± 1.3 | (1.3 – 5.6) |
| Neuropsychological test | ||||
| Trail making test (s) | 49 ± 16 | (34 - 77) | 50 ± 16 | (25 - 72) |
| Digit symbol test (gross point) | 38 ± 10 | (21 - 53) | 37 ± 15 | (19 - 63) |
Table 3 Changes in laboratory and neuropsychological tests after BCAA and placebo administration
| BCAA group | Placebo group | |||||||
| Before | After | Before | After | |||||
| Laboratory variables | ||||||||
| Plasma ammonia (µM/L) | 35 ± 20 | (9 - 79) | 31 ± 14 | (8 - 54) | 36 ± 20 | (7 - 74) | 37 ± 14 | (17 - 58) |
| BCAA to tyrosine ratio | 3.7 ± 1.2 | (2.3 - 7) | 16.7 ± 3.4b | (13.1 - 24.6) | 3 ± 1.3 | (1.3 - 5.6) | 3.1 ± 1.3 | (1.6 - 5.7) |
| Neuropsychological test | ||||||||
| Trail making test (s) | 49 ± 16 | (34 - 77) | 47 ± 13 | (30 - 72) | 50 ± 16 | (25 - 72) | 51 ± 15 | (29 - 75) |
| Digit symbol test (goss point) | 38 ± 10 | (21 - 53) | 45 ± 14 | (21 - 71) | 37 ± 15 | (19 - 63) | 40 ± 14 | (23 - 61) |
- Citation: Yamamoto M, Iwasa M, Matsumura K, Nakagawa Y, Fujita N, Kobayashi Y, Kaito M, Takeda K, Adachi Y. Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis. World J Gastroenterol 2005; 11(43): 6792-6799
- URL: https://www.wjgnet.com/1007-9327/full/v11/i43/6792.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i43.6792